Veeva Systems (NYSE: VEEV) today announced that Lotus Clinical Research expanded its partnership with Veeva and broadened its adoption of Veeva Vault Clinical Suite, a strategic move to strengthen its service delivery and efficiency.
| Fast-growing CRO utilizes Veeva Vault Clinical Suite to substantially decrease startup time NEW PROVIDENCE, N.J. and PLEASANTON, Calif., May 30, 2023 /PRNewswire/ -- Veeva Systems, Inc. (NYSE: VEEV) today announced that Lotus Clinical Research, LLC expanded its partnership with Veeva and broadened its adoption of Veeva Vault Clinical Suite, a strategic move to strengthen its service delivery and efficiency. This builds on Lotus’ existing use of Vault Clinical Suite to implement swifter and more connected studies. The successful incorporation of Veeva Vault CDMS, Veeva Vault eTMF, and Veeva Vault CTMS has effectively scaled Lotus’ trial operations while sustaining the highest quality standards. With a unified clinical ecosystem, Lotus has significantly reduced study startup time.
Lotus President, Bill Martin, elaborated on the benefits of the partnership with Veeva, “This collaboration enables Lotus to conduct a higher volume of clinical trials while improving coordination with sponsors and clinical trial sites. Easy-to-use, integrated clinical applications are vital for Lotus as we continue to diversify our disease area expertise and increase our site interactions and patient recruitment.” As a rapidly expanding CRO, Lotus sought to develop an adaptable, connected, and scalable infrastructure to keep pace with its growth. The internal team of trained programmers is now leveraging Vault CDMS, its primary clinical data management system, to design studies entirely in-house. This has resulted in faster delivery of electronic data capture (EDC) study builds, significantly cutting study startup time. Using integrated applications on a single platform has enabled Lotus to effortlessly share questionnaires and metrics between Vault CDMS and Vault CTMS, simplifying monitoring reports. With a single source for documentation and a seamless flow of data and documents across clinical applications, Lotus can increase compliance, ensure rapid study initiation, and deliver a better site experience. These advancements have propelled Lotus’ transition from a company with an initial focus on acute pain and CNS to one that supports all facets of clinical research. “We’re proud to grow our five-plus year partnership with Lotus, bringing together their experience and knowledge executing complex clinical trials with our technology expertise,” said Jon Young, director, Veeva Vault Clinical strategy. “With Veeva Vault Clinical Suite, Lotus can provide value-added services to customers and streamline how they work with sites for greater speed and agility.” About Lotus Clinical Research Lotus is unique to other CROs in that they are owned by Emerge Holdco, LLC, which also owns Evolution Research Group, LLC (ERG), a leading clinical site organization with 20+ wholly owned clinical research sites around the US, with over 450 beds, conducting early and late phase complex trials in both healthy volunteers and highly specialized, diverse populations. The successful conduct of clinical trials at Lotus is a result of the therapeutic expertise and the superior level of talent across the medical, operational, and support functions. For more information, visit lotuscr.com. About Veeva Systems Veeva Forward-looking Statements Contact: Deivis Mercado
SOURCE Veeva Systems | ||
Company Codes: NYSE:VEEV |
View original content to download multimedia:
